Inspection Record

Ajinomoto Company Inc. — FDA 483 Findings

US FDAInspected 2025-02-21Published 2026-05-06 3 findingsLaboratory and QC controlsStability and storageDeviation, CAPA, and investigation

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

The laboratory sample preparation worksheets used for preparation of all samples in the laboratory do not have a system to control and record issuance of the worksheets or to identify issuance of multiple worksheets for the same sample preparation.

2Stability and storage

There is no data to support that the (b)used in the construction of production tanks, including the (b)(4) Tank, L Tank, (b)(4) Storage Tanks, and the [ (b) (4) Tank, used to produce all APIs manufactured at the site is not additive to the APIs.

3Deviation, CAPA, and investigation

Five out of five investigations into production deviations and laboratory out -of -specification results reviewed did not identify the true root cause and supported action to be taken to prevent a reoccurrence of the issue.

About this record

Extracted automatically from the document US FDA published on 2026-05-06. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Ajinomoto Company Inc. company profile — full history US FDA documents, 2026 Go to Findings search